Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 16/20 | 0.98 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.77 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.77 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluprostenol SCHEMBL10015915 | 0.99 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL230607 | 0.99 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL16414486 | 0.99 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL24342073 | 0.99 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL13260302 | 0.99 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL24342036 | 0.99 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL6750653 | 0.99 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL2744986 | 0.99 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL20860290 | 0.99 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL16414497 | 0.99 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-4202880-A | SUSTAINED RELEASE | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-05-13 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0245858-B1 | ADHESIVE FOR PERCUTANEOUS ADMINISTRATION | TAKIRON CO. LTD. (JP) | 1992-07-29 | — | — | EP | disclosed |
| US-4997656-A | Layer containing heat-and water-sensitive amphiphilic polymer and biologically active agent | TAKIRON CO., LTD. (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0245858-A2 | Adhesive for percutaneous administration | TAKIRON CO. LTD. (JP) | 1987-11-19 | — | — | EP | disclosed |
| US-4235988-A | HYDROPHILIC BLOCK POLYOXYALKYLENE-POLYURETHANE COPOLYMER CARRIER WHICH PERMITS SUSTAINED RELEASE OF THE DRUG | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-11-25 | — | — | US | disclosed |
| US-4202880-A | SUSTAINED RELEASE | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | PTGFR 3278/4885PTGER3 3331/4885ABCC4 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.